OverviewChartTechnicalNewsTraderScreen

Cellectis SA/  FR0010425595  /

Euronext - Paris
11/8/2024  5:35:22 PM Chg. +0.022 Volume Bid5:40:00 PM Ask5:40:00 PM High Low
1.710EUR +1.30% 20,226
Turnover: 34,218.274		 1.674Bid Size: 153 1.718Ask Size: 33 1.714 1.672
GlobeNewswire 8/26 Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Rec...
GlobeNewswire 8/8 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First...
GlobeNewswire 8/7 Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update 
GlobeNewswire 8/7 Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
GlobeNewswire 8/6 Cellectis Provides Financial Results for the Second Quarter 2024
GlobeNewswire 8/1 FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
GlobeNewswire 7/25 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product c...
GlobeNewswire 7/16 Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as D...
GlobeNewswire 7/1 Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase ...
GlobeNewswire 6/28 Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewswire 6/20 Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewswire 6/20 Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cem...
GlobeNewswire 6/12 Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
GlobeNewswire 6/4 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients wi...
GlobeNewswire 5/29 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
GlobeNewswire 5/28 Cellectis Reports Financial Results for First Quarter 2024
GlobeNewswire 5/27 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
GlobeNewswire 5/13 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire 5/9 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire 5/6 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire 5/2 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
GlobeNewswire 4/29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
GlobeNewswire 4/26 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...
GlobeNewswire 4/22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...
GlobeNewswire 4/10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...